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Synopsis
aHUS (atypical haemolytic uraemic syndrome), AMD (age-related macular degeneration) and other diseases are
associated with defective AP (alternative pathway) regulation. CFH (complement factor H), CFI (complement factor I),
MCP (membrane cofactor protein) and C3 exhibited the most disease-associated genetic alterations in the AP. Our
interactive structural database for these was updated with a total of 324 genetic alterations. A consensus structure
for the SCR (short complement regulator) domain showed that the majority (37%) of SCR mutations occurred at its
hypervariable loop and its four conserved Cys residues. Mapping 113 missense mutations onto the CFH structure
showed that over half occurred in the C-terminal domains SCR-15 to -20. In particular, SCR-20 with the highest
total of affected residues is associated with binding to C3d and heparin-like oligosaccharides. No clustering of 49
missense mutations in CFI was seen. In MCP, SCR-3 was the most affected by 23 missense mutations. In C3, the
neighbouring thioester and MG (macroglobulin) domains exhibited most of 47 missense mutations. The mutations in
the regulators CFH, CFI and MCP involve loss-of-function, whereas those for C3 involve gain-of-function. This combined
update emphasizes the importance of the complement AP in inflammatory disease, clarifies the functionally important
regions in these proteins, and will facilitate diagnosis and therapy.
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INTRODUCTION
Starting from the first reports of complement disease-associated
mutations [1], genetic alterations in four CFH (complement factor
H), CFI (complement factor I), MCP (membrane cofactor pro-
tein) and complement C3 have increasingly been associated with
immune disorders [2–4]. HUS (haemolytic uraemic syndrome)
is characterized by a phenotype of microangiopathic haemolytic
anaemia, thrombocytopenia and acute renal failure in affected in-
dividuals. While the majority of diarrhoeal HUS cases are caused
by toxic Escherichia coli bacteria, other cases are non-diarrhoeal
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associated and have a poorer prognosis. This is termed aHUS
(atypical HUS). Initially aHUS was strongly associated with
mutations in the gene encoding the complement regulator CFH
[5]. CFH is a central regulator in the AP (alternative pathway)
of activation, in which it acts as a cofactor for the CFI in the
proteolytic inactivation of the central complement protein C3b
to form iC3b [6,7]. CFH also accelerates the decay of the C3
convertase C3bBb, and competes with Factor B for binding to
C3b. CFH consists of 20 SCR (short complement regulator) do-
mains, also known as short consensus repeat, complement con-
trol protein or sushi domains, each of length about 61 residues
(Figure 1a).
c© 2014 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/)
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Figure 1 Location of 311 disease-associated mutations in the domain structures of CFH, CFI, MCP and C3
The ten intron and splicing mutations are not shown (Supplementary Table S1), making a total of 324. CFH, CFI, MCP and
C3 possess 20, five, four and 13 domains respectively, which are drawn to scale. The reported sequence mutations are
shown linked with the domain in which each is located. The signal peptide is shown in grey. The sequence numbering of each
domain is indicated. (a) CFH with 161 mutations (SCR = short complement regulator). (b) CFI with 63 mutations (FIMAC = FI
membrane attack complex; SRCR = scavenger receptor cysteine-rich; LDLr = low-density lipoprotein receptor; abbreviated
as L1 and L2). (c) MCP with 41 mutations (ST = serine/threonine-rich region; TM = transmembrane helix region; Cy =
cytoplasmic region). (d) C3 with 48 mutations (MG = macroglobulin; TED, thioester domain; CUB, C1r/C1s-Uegf-Bmp1
domain; and the C345C, LNK and ANA domains). Note that each of the MG6 and CUB domains is divided into two parts
in the C3 sequence).
CFI, MCP and C3 were subsequently associated with aHUS
mutations. Mutations in CFH and these three other proteins result
in impaired protection of host surfaces against complement activ-
ation and lead to endothelial cell activation [8]. The protease CFI
is formed from a heavy chain comprising a FIMAC (FI mem-
brane attack complex) domain, an SRCR (scavenger receptor
cysteine-rich) domain (also known as a CD5 domain: cluster of
differentiation 5) and two LDLr (low-density lipoprotein receptor
domains [9] (Figure 1b). Its light chain is formed from the cata-
lytic SP (serine protease) domain. CFI mutations were identified
in its gene [10–12]. MCP is a widely expressed transmembrane
protein that inhibits AP activation on host cells. In combination
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Mutations in complement regulatory proteins
with CFI, MCP is a cofactor for the degradation of activated
C3b and C4b bound to cell surfaces. The extracellular amino
terminus of MCP consists of four SCR domains. Following this
is an alternatively spliced region for extensive glycosylation, a
transmembrane domain and a cytoplasmic domain (Figure 1c).
MCP mutations were identified in its gene [11,13–16]. C3 is the
most abundant complement component in plasma, occurring at
about 1.0 mg/ml, and its proteolytic conversion to active C3b by
the removal of its ANA domain is the central event in comple-
ment activation. C3 is formed from eight MG (macroglobulin)
domains, together with the TED (thioester-containing domain)
domain containing the C3b active site, the CUB (C1r/C1s–Uegf–
Bmp1) domain that links the TED and MG domains, and the
C345C, LNK and ANA domains (Figure 1d). On activation to
C3b, the thioester forms covalent bridges with antigenic surfaces.
C3 mutations were identified in its gene [17]. Mutations in other
complement proteins including factor B, thrombomodulin and the
CFH-related proteins also show associations with these diseases,
but in low occurrences [3,18,19].
Mutational web databases provide essential repositories for
functional, diagnostic and therapeutic approaches [2,20]. An in-
teractive FH–HUS web database (http://www.FH–HUS.org) was
first set up in November 2004 for mutations and structural mod-
els for CFH [5]. The update of June 2006 included mutations for
CFI and MCP alongside structural models for their domains, and
also included SNPs (single nucleotide polymorphisms) for these
three proteins that show disease-risk associations for conditions
such as age-related macular degeneration [2]. This web resource
with 167 alterations received 19800 hits by June 2014. Since
2006, mutations within C3 were recognized to be important in
aHUS and other diseases. Here we extend the database to include
C3, and map the mutations to improved protein structural models
for CFH and crystal structures for CFI, MCP and C3 [21–25].
The database now contains a new total of 324 mutations in June
2014. This enhanced dataset permits a critical review of genetic
alterations in terms of function and structure. In terms of a con-
sensus SCR structure, the distribution of 107 CFH and 22 MCP
missense mutations indicate better the functional importance of
the hypervariable SCR loop. The CFH mutations at its C-terminal
domains are rationalized in terms of a recent co-operative two-
site binding model for CFH at host cell surfaces [26]. In C3 and
C3b, the proximity of the functionally important TED and MG-
2 domains accounts for the highest number of mutations. The
updated database provides new clarification of the role of the
complement proteins in inflammatory diseases, including AMD
and aHUS, and suggests new approaches to analyse the functional
outcomes of such modifications.
EXPERIMENTAL
Mutation database updates
The FH–HUS mutation database is available at the follow-
ing URL http://www.FH–HUS.org. It is installed on a server
in the Department of Structural and Molecular Biology at
the University College London, and backed up nightly to
an off-site server. The database is constructed using mySQL
(http://www.mysql.com) and is displayed and navigated on the
web via PHP (http://www.php.com), Javascript and HTML pro-
gramming. The database was extended to include a total of 324
mutations and new structural models for CFH, CFI, MCP and
C3. Quick, basic and advanced searches can be performed for
CFH, CFI, MCP and C3 mutations. Mutation maps based on
both protein and nucleotide sequences are available for each pro-
tein. Statistics show the distribution of mutations in the domains
of all four proteins (Figure 1). Molecular views of each missense
mutation in each protein are available through the JMol java
applet (http://jmol.sourceforge.net/) in order to permit a better
understanding of its structural context.
Sources of mutational data in CFH, CFI, MCP
and C3
All the genetic alterations within the FH–HUS database
are numbered according to the HGVS (http://www.hgvs.
org/mutnomen/) guidelines for mutation nomenclature [27],
where nucleotide + 1 refers to the A of the initiating ATG codon.
Amino acids are also numbered starting from the initiating Met
residue. To avoid confusion, the website now includes a descrip-
tion of how the alteration was first reported if the original num-
bering was not consistent with HGVS guidelines.
Rare genetic alterations in populations that are thought to be
the major cause of disease or deficiency are termed disease-
associated mutations. SNPs are defined as point mutations that
occur in over 1 % of the general population. To avoid confu-
sion, SNPs that are not associated with disease are termed non-
disease causing polymorphisms, and SNPs associated with a dis-
ease risk are referred to as disease-associated polymorphisms.
The 167 genetic alterations in CFH, CFI and MCP from previous
[2] were retained in this database update. Additional mutations
were identified from surveys of the literature database PubMed
(http://www.ncbi.nih.gov/entrez/query.fcgi), and are referenced
in Supplementary Table S1 [28–70]. Additional mutations were
also identified by searching the Human Gene Mutation database
(http://archive.uwcm.ac.uk/uwcm/mg/hgmd0.html). The data-
base search was also extended to include records from the SNP
database (http://www.ncbi.nlm.nih.gov/projects/SNP/). This res-
ulted in 324 mutations.
Structural models for the consensus SCR domain,
CFH, CFI, MCP and C3
SCR domains generally contain about 60 residues arranged as
six to eight β-strands numbered β1 to β8 with a hypervariable
sequence loop between strandsβ2 andβ3 (Figure 2) [2]. The con-
sensus sequence from 124 human complement SCR sequences
is shown in Figure 2(c). A total of 27 unique experimental SCR
structures were superimposed to model a consensus SCR struc-
ture (Figure 2d) as previous that incorporated the six central
β-strands β2–β7. The N-terminal strand (β1) and the C-terminal
strand (β8) were missing from this because of the absence of
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Figure 2 Location of CFH and MCP mutations on a consensus SCR domain
The CFH and MCP missense mutations are usefully represented in terms of a consensus sequence and structure for a
single SCR domain. (a) Superimposition of crystal structures available for ten SCR domains in CFH, shown as a secondary
structure cartoon tube (Methods). The locations of six β -strands β2–β7 were labelled, together with the N-terminus (N)
and C-terminus (C). The superimposition utilised the conserved four Cys and one Trp residues within each SCR domain,
except for SCR-10 which does not contain this conserved Trp residue. (b) Superimposition of the four SCR domains in
MCP, shown as a secondary structure cartoon, in the same orientation as (a). The superimposition was performed as
in (a). The locations of six observed β -strands β2 and β4–β8 were labelled. (c) The consensus SCR sequence shows the
most commonly occurring residue at each position. The available 106 CFH (red) and 22 MCP (blue) missense mutations
are mapped to their positions within the consensus sequence. The 50 intron, deletion and silent mutations and five SCR
linker missense mutations in CFH are not shown. The 21 intron, deletion and silent mutations and four non-SCR missense
mutations in MCP are likewise not shown. Where mutations align with insertions outside the consensus structure, the
mutation is mapped to the position before the insertion. The six main β -strands β2 to β7 in SCR domains are shown in
yellow as labelled. Mutations for the five residues 11–15 in the hypervariable loop between β2 and β3 are shown against
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Mutations in complement regulatory proteins
Table 1 Summary of genetic and protein identifiers for CFH, CFI, MCP and C3
UniProt, Universal Protein Resource; OMIM, Online Mendelian Inheritance in Man (http://www.omim.org/). The reference sequences for the protein
and genetic sequences are taken from the RefSeq database with the following accession numbers NM_000186.2 (CFH), NM_000204.2 (CFI),
NM_002389.4 (MCP) and NM_000064.2 (C3).
Name Gene
Chromosome
location
UniProt
identifier Protein product
Amino acid
length
Domain
organization Genetic disorder
OMIM
identifier
CFH CFH 1q31.3 P08603 Complement
factor H (OMIM
134370)
1231 SCR-1 to
SCR-20
Basal laminar
drusen
126700
Complement
factor H
deficiency
609814
AHUS1 235400
Macular
degeneration,
age-related, 4
610698
CFI CFI 4q25 P05156 Complement
factor I (OMIM
217030)
583 FIMAC, SRCR,
LDLR-1,
LDLR-2, SP
Complement
factor I
deficiency
610984
AHUS3 612923
Macular
degeneration,
age-related, 13
615439
Partial deficiency
of Complement
C4
120790
MCP CD46 1q32.2 P15529 Membrane
cofactor
protein (OMIM
120920)
392 SCR-1 to
SCR-4
Haemolytic
uremic
syndrome,
atypical, 2
(AHUS2)
612922
C3 C3 19p13.3 P01024 Complement C3
(OMIM
120700)
1663 MG1-MG8,
ANA, TED,
CUB,
C345C, LNK
C3 deficiency
Macular
degeneration,
age-related, 9
613779
611378
AHUS5 612925
residues preceding the first and last cysteine of the SCR domain.
The averaged side-chain accessibility of the 27 experimental SCR
structures aligned to the consensus structure is also shown in
Figure 2(c). These structural information were computed from
DSSP software for secondary structure assignments and side-
chain surface accessibilities [71].
For full-length CFH, two structures determined by scattering
modelling were used. One showed a more compact N-terminal
region and more extended C-terminal region (PDB code 3GAV)
[22]. The other showed a more extended N-terminal region and
a more compact C-terminal region [23]. For the 20 individual
domains in CFH, a total of 17 experimental structures were cur-
rently known. These were SCR-1/4 (PDB code 2WII), SCR-
5, SCR-6/8 (PDB code 2V8E), SCR-10/11 (PDB code 4B2R),
SCR-11/12 (PDB code 4B2S), SCR-12/13 (PDB code 2KMS),
SCR-15/16 (PDB code 1HFI), SCR-18/20 (PDB code 3SW0) and
SCR-19/20 (PDB code 2G7I) [72–79]. The seven structures for
SCR-5, SCR-10/13 and SCR-15/16 were determined by NMR;
the other ten were crystal structures which were considered to be
more accurate. Previously, for the 2006 database, only five struc-
tures were known and thus used, with the other 15 domains being
represented by homology models [2,5]. For the present study, the
homology models from previous for SCR-9, SCR-14 and SCR17
were retained.
Crystal structures were used for CFI, MCP and C3. The struc-
ture of the five domains in CFI was represented by its crystal
a green background. The consensus solvent side-chain accessibilities are numbered from 0 to 9, where 0 denotes 0–9%
accessibility, 1 denotes 10–19% accessibility, etc. Residue side chains with values of 0 and 1 are considered to be buried.
(d) Front and back view of a secondary structure cartoon derived from the consensus SCR structure. The white numbers
in the spheres correspond to the residue position in the consensus sequence. Mutations are highlighted as blue spheres.
The size of the individual spheres indicates the number of mutations at that position, and ranges from one to nine.
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structure (PDB code 2XRC) [25]. This replaced the five separ-
ate homology models used previously [2]. The structure of the
SCR-1/4 domains in MCP was taken from its crystal structure
(PDB code 3O8E) [24]. The MCP crystal structure superseded
NMR structures previously used for SCR-1 and SCR-2 of MCP,
and homology models for SCR-3/4 [2,80]. The structure of the
13 domains in C3 was taken from its crystal structure (PDB code
2A73) [21].
RESULTS
Missense mutations within SCR domains
The SCR domain is the most abundant domain type in the com-
plement proteins, and both CFH and MCP are entirely composed
of SCR domains (Figures 1a and 1c). All 17 structures for CFH
were superimposed on each other using their five conserved Cys
and Trp residues. The secondary structures of SCR-1/4, SCR-
6/8, SCR-10/12 and SCR-18/19 were well matched against each
other, apart from minor deviations seen for SCR-6/7. However,
the SCR-13 and SCR-20 structures deviated notably from this su-
perimposed view. Crystal structures for SCR-6/7 showed similar
β-strands, as also the NMR structures for SCR-5 and SCR-15/16.
In the ten best-matched SCR structures, the six superimposed
β-strands β2–β7 were readily visible (Figure 2a). The superim-
position of the four SCR-1/4 domains in MCP also showed good
matches with each other (Figure 2b), in which the β-strands
β2 and β4–β8 were readily visible. Molecular graphics views
showed that the best-conserved secondary structure occurred in
the four-stranded anti-parallel β-sheet formed from β-strands β2,
β4, β6 and β7. The four conserved Cys residues were bridged in
the order C1–C3 and C2–C4 (residue pairs 1–39 and 26–49 in the
consensus sequence). Since C2 occurred on β-strand β2 and C3
occurred on β-strand β6, the two disulphide bridges were crucial
for the structural integrity of the SCR domain. The two-stranded
anti-parallel β-sheetβ5 andβ8 also showed good conservation. It
was relevant that all six β-strands β3–β8 were successfully iden-
tified from secondary structure predictions prior to the first SCR
structure determinations, together with the partial identification
of β-strand β2 [2,81]. This success indicated the degree to which
the β-sheet structure in SCR domains is well-defined. The most
structural variability between SCR domains occurred between
the β-strands β2 and β3 at the bottom of Figures 2(a) and 2(b)
(which has been termed the hypervariable loop for reason of its
sequence diversity), together with partial variability between the
β-strands β5 and β6 at the top of Figures 2(a) and 2(b).
Disorders in plasma proteins have been classified into two
types [5,20]. Type I was defined when the protein plasma level
was low and indicated a secretory defect or rapid degradation.
Type II mutations were associated with normal plasma levels,
being defined to correspond to a functional defect in activity. For
CFH, these assignments were not straightforward for reasons of
the large variation of FH levels in plasma and the different meth-
ods used for the clinical assays. We thus followed our previous
analysis [2,5]. The comparison of the CFH and MCP mutational
phenotypes with their protein structures was facilitated by the use
of a consensus SCR domain. Such a consensus SCR structure and
sequence displayed all six β-strands β2–β7 (Figure 2c) [2]. All
the 107 CFH and 22 MCP missense mutations occurred within
the 24 SCR domains; only one was found in a CFH inter-SCR
linker between two domains (Figure 1a). This outcome suggested
that the linker regions have low functional significance.
Two groups of SCR mutations attracted attention. Firstly, 25
of the 129 mutations (19 %) occurred in the five residues of the
hypervariable loop between β-strands β2 and β3. In contrast,
the corresponding loop between the β-strands β5 and β6 only
contained eight mutations. Most of these 25 mutations showed
Type II phenotypes [2], and all were surface-exposed. This sug-
gested that these mutations were associated with functional in-
teractions. Secondly, 23 of the 129 mutations (18 %) affected one
of the four Cys residues that stabilized the central β-sheet. Most
of these 23 mutations showed Type I phenotypes [2], and all had
low-solvent exposures. This suggested that these Cys mutations
were associated with structural instabilities and incorrect protein
folding and expression levels.
The remaining 81 (63 %) of the 129 mutations were distributed
across the remaining 41 SCR residues, with between 0 and 5
occurrences at each residue (Figure 2c). A large majority of these
41 residues (i.e. 34) were solvent-exposed, and contained 62
missense mutations. Thus most of the mutations were predicted
to be Type II that probably affected functional protein–protein
interactions in CFH and MCP. The remaining seven residues were
buried with low accessibilities of 0–2, and were associated with
19 missense mutations; these residue changes were presumed to
be Type I that affected protein folding and stability.
Analysis of disease-associated mutations within
CFH
Of the 163 mutations now known for the complement regulator
CFH (Supplementary Table S1), 113 were missense mutations,
21 were nonsense, 12 were deletions (of which three were in-
frame), eight were silent, five were frameshifts, two were intro-
genic mutations, one was an insertion and one was a splicing
event. The former 2006 database contained 100 genetic altera-
tions within CFH [2]. The current distribution of 161 non-intronic
mutations (Figure 1a) gave a frequency of 13 non-intronic muta-
tions/100 residues. The 113 missense mutations were mapped
onto the CFH sequence in Supplementary Figure S1, together
with their computed secondary structures and side-chain access-
ibility for the 17 known SCR structures and three homology
models. The majority of mutations were found in SCR-20 with
39, followed by SCR-19 with 13 mutations, SCR-15 with 12
mutations, SCR-17 with ten mutations and SCR-16 with eight
mutations. The disproportionately high proportion of 33 % (52
out of 160 mutations) in SCR-19/20 was similar to that of 39 %
(33 out of 84 mutations) for SCR-19/20 in the 2006 database [2].
A disproportionately high proportion of 31 mutations (19 %) in
SCR-15/18 was again observed, similar to that of 20 mutations
(24 %) reported in 2006 for SCR-15/18. The current number of
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Mutations in complement regulatory proteins
mutations in other regions of CFH, especially at SCR-1/4 and
SCR-6/8, was relatively low.
A structural understanding of the CFH mutations required a
molecular structure for CFH, however intact CFH has not been
crystallised to date. Fortunately, experimental structures were
now known for 17 of the 20 SCR domains, with many from crys-
tallography (Methods). Most SCR domains in CFH possessed
typical SCR structures with up to eight β-strands (Figure 2a); the
exceptions were SCR-13 and SCR-20. The middle SCR domains
of CFH possessed shorter sequences, longer inter-domain links
and higher glycosylation levels, suggesting that these middle do-
mains acted as conformational spacers. Scattering modelling pro-
duced the first experimental molecular structures for full-length
CFH [22,23]. This modelling was based on molecular structures
for all 20 SCR domains joined together; conformational ran-
domization was applied to the inter-SCR linkers to create trial
CFH domain arrangements in all conformations. The scattering
fits showed that only the folded-back domain structures with an
overall length of 40 nm fitted the data, not the extended ones
with a length of up to 73 nm. Two distinct CFH models had been
determined, both giving indistinguishable scattering curve fits.
In the first, SCR-13/20 is extended in its domain arrangement
and SCR-1/12 is looped back (Figure 3a) [22]. In the second,
the SCR-1/7 domains are extended and SCR-8/20 is looped back
(Figure 3b) [23]. The second model was more easily docked with
the C3b–CFH crystal structure in which the SCR-1/4 domain ar-
rangement was extended [63]. As the SCR-6/8 and SCR-19/20
domains may potentially bind to a surface, both CFH structures
were consistent with the recently–proposed bivalent and cooper-
ative binding mechanism of CFH to polyanionic oligosaccharides
on a host cell surface [26,82].
CFH possessed major functional activities at its N-terminal
SCR-1/4 and C-terminal SCR-19/20 domains, together with an-
other activity at the SCR-6/8 domains [83]. The mapping of the
112 CFH missense mutations onto 100 mutated residues showed
that the mutations occurred throughout the CFH structure. The
availability of 17 experimental SCR structures for CFH means
that side-chain solvent accessibilities were more precisely estim-
ated. Inspection of these accessibilities for the CFH mutations
showed that 67 out of 100 mutated residues were solvent ex-
posed, while 33 out of 100 corresponded to buried side chains
with low-solvent accessibilities of 0–2 (Supplementary Figure
S2).
Mutations were not evenly distributed in CFH. The muta-
tional hotspot at SCR-19/20 showed 22 solvent-exposed side-
chains in 31 mutated residues. The frequency of non-intronic
mutations/100 residues rose from 13 for full-length CFH to 44 in
SCR-19/20. This abundance in SCR-19/20 correlated with the
presence of key binding sites for C3b, C3d and heparin-like lig-
ands. The best understood were the two binding sites for C3d
on SCR-19/20, one on each domain [84,85], which may account
for the high proportion of mutations in SCR-19/20. C-reactive
protein was also reported to bind to SCR-16/20 [86]. The propor-
tionately higher number of SCR-15/17 mutations implied that
SCR-15/17 may be functionally significant, even though these
did not contain reported ligand-binding sites. The folded-back
domain arrangement of SCR-15/17 in the second CFH model
(Figure 3b) suggested that this defined the separation of the two
heparin-like binding sites at SCR-6/8 and SCR-19/20 in the bi-
valent binding of CFH to host cell surfaces. If so, mutations in
SCR-15/17 would alter the separation between these two heparin
sites and disrupt CFH binding to host cell surfaces. Curiously,
despite the well-characterized binding of SCR-1/4 to C3b [72]
and that of heparin and C-reactive protein to SCR-6/8 [82,86],
fewer mutations occurred in the SCR-1/4 and the SCR-6/8
regions.
Analysis of disease-associated mutations within
CFI
Of the 64 mutations currently known for the regulatory protease
CFI (Supplementary Table S1), 49 were missense mutations, six
were nonsense, two were deletions, one was silent, one was a
frameshift, two were insertions and one was a splicing event. The
distribution of the 63 non-intronic mutations was summarized
in Figure 1(b). The 49 missense mutations were mapped onto
the CFI sequence in Supplementary Figure S2, together with
their computed secondary structures and side-chain accessibilit-
ies. The former 2006 database had 24 genetic alterations within
CFI, with only seven missense mutations and three nonsense
mutations [2]. The present database identified 49 missense muta-
tions in all five domains of CFI. Although most (18) were within
the SP domain, this was as expected because the SP domain
was the biggest one. All five domains showed similar mutational
frequencies of 6–14 non-intronic mutations/100 residues. Unlike
CFH, no sequence mutational hotspots or unaffected parts of CFI
occurred that might reflect different functional activity.
The CFI crystal structure located the residues in CFI, except-
ing those not visible through protein disorder at surface loops
and its compact domain arrangement [25]. The compact do-
main structure (Figure 4a) was similar to that first established
by solution scattering modelling [9]. Compared with the five
separate domain structures used previously [2], the crystal struc-
ture provided accurate solvent side-chain accessibilities. Thus
19 out of 48 missense mutations corresponded to buried side
chains with low-solvent accessibilities of 0–2 (Supplementary
Figure S2). This proportion of 40 % buried mutated residues in
CFI was higher than those of 23 % buried mutated residues in
the consensus SCR and 33 % for the buried mutated residues in
CFH. This 40 % proportion was attributed to the compact CFI
structure, meaning that mutations may perturb this arrangement,
compared to the more extended structures of CFH and MCP. Al-
though several CFI missense mutations were close to the catalytic
triad (Figure 4a), no mutational clustering was seen in the CFI
structure.
Analysis of disease-associated mutations within
MCP
Of the 49 mutations presently known for MCP (Supplementary
Table S1), 26 were missense mutations, four were nonsense, six
were deletions, three were silent, one was a frameshift, six were
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Figure 3 Distribution of the 100 residues associated with missense mutations in CFH
The 100 residues associated with 113 missense mutations are shown as blue spheres and the number of affected
residues in each SCR domain is written within brackets. The mutations are identified in Supplementary Figure S1. The
20 domain solution structure of CFH is shown as a secondary structure ribbon in two alternative views. One corresponds
to a more compact N-terminal region and a more extended C-terminal region. The other corresponds to a more extended
N-terminal region and a more compact C-terminal region. The scattering modelling of CFH presents these as two equivalent
best-fit structures. The location of the C3b-binding site at SCR-1/4 is indicated by blue lines. The two sites for the heparin
and C-reactive protein-binding sites are shown by red lines. C3b and C3d also bind at the C-terminus.
introgenic mutations and three were polymorphisms. The total of
26 missense mutations is increased compared to ten previously
[2]. The distribution of 43 non-intronic mutations was summar-
ized in Figure 1(c). The four extracellular SCR domains showed
similar mutational frequencies of 15 non-intronic mutations/100
residues. The 26 missense mutations were mapped onto the MCP
sequence in Supplementary Figure S3, together with their sec-
ondary structures and side-chain accessibility. The most missense
mutations occurred in SCR-3; this abundance may be correlated
with surface exposed residues associated with both C3b and C4b
binding to MCP [87].
The MCP crystal structure (Figure 4b) revealed an exten-
ded four-domain arrangement [24]. Of the 23 missense muta-
tions, 13 were located at solvent-accessible sidechains, while ten
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Mutations in complement regulatory proteins
Figure 4 Distribution of the CFI and MCP missense mutations in
their crystal structures
The domains are shown as a secondary structure ribbon, coloured from
blue (N-terminus) to red (C-terminus) in a rainbow scheme. The number
of mutations within each domain is written within brackets, and the
mutations are identified in Supplementary Figures S2 and S3. (a) Loca-
tion of 40 residues associated with 41 missense mutations are shown
as dark blue spheres within the crystal structure of CFI. Factor I is a het-
erodimer consisting of a non-catalytic heavy chain (FIMAC domain, blue;
SRCR domain, green; LDLr-1 domain, orange; LDLr-2 domain, yellow),
and linked by a disulphide bound to a catalytic light chain (SP domain,
red). This colour scheme follows that for the sequence in Supplement-
ary Figure S2. For the linker, one missense mutation is not shown for
reason of disorder in the crystal structure, making a total of two. For
the SP domain, seven missense mutations are not shown for reason
of disorder in the crystal structure, making a total of 25. The catalytic
triad residues in the SP domain are shown as orange spheres. (b) Loc-
ation of 23 residues associated with 23 missense mutations within
the crystal structure of the extracellular domains of MCP. Mutations
are mostly found in the four extracellular SCR domains (SCR-1, cyan;
SCR-2, green; SCR-3, orange; SCR-4, red). This colour scheme follows
that for the sequence in Supplementary Figure S3.
corresponded to buried sidechains with low solvent accessibil-
ities of 0–2 (Supplementary Figure S3). MCP showed a higher
proportion (43 %) of buried missense mutated side chains than
CFH (33 %). This increased proportion was attributed to the im-
portance of the four Cys residues in stabilizing the β-sheet SCR
structure. Five of these ten buried residues in MCP occurred at
conserved Cys residues.
Analysis of disease-associated mutations within C3
Of the 48 mutations presently known for C3 (Supplementary
Table S1), 47 were missense mutations, and one was a nonsense
mutation. No significant number of C3 mutations was known pre-
viously [2]. The 47 missense mutations were mapped onto the C3
sequence in Supplementary Figure S4, together with their second-
ary structures and side-chain accessibilities. The most missense
mutations were found in the TED domain with 15, followed by
the MG2 and MG5 domains with 4–5 in each, and the C345C
domain with four (Figure 1d). The mutational frequencies in
the TED, MG2 and MG5 domains were five non-intronic muta-
tions/100 residues, that in the ANA domain was 3.5 non-intronic
mutations/100 residues, and that in the C345C domain was 2.7
non-intronic mutations/100 residues. These mutational frequen-
cies were less than half of those in CFH, CFI and MCP.
The C3 crystal structure with all 13 domains was used for
mutational analyses (Figure 5) [21]. The ANA domain was
removed in activated C3b, thus this crystal structure was not
used, but was made available on our updated web site at
http://www.FH–HUS.org. In the C3b crystal structure, which
was crystallized in low-salt conditions, the TED and CUB do-
mains (red and purple in Figure 5) moved downwards to form a
TED–MG1 domain pair (Figure 6a). In more physiological salt
buffers, the TED–MG1 domain pair in C3u and C3b became sep-
arated [88–90]. The C3 crystal structure showed the inter-domain
packing arrangement, although these underwent rearrangement in
C3b. Inspection of the solvent side-chain accessibilities showed
that 12 out of 46 missense mutations corresponded to buried side
chains with low-solvent accessibilities of 0–2 (Supplementary
Figure S4). This 26 % proportion of buried missense residues in
C3 was the lowest compared with CFH (33 %), CFI (40 %) and
MCP (43 %). This was explained by the paucity of Cys residues in
C3 compared to those of the Cys-rich CFH, CFI and MCP struc-
tures, thus making the C3 structure less vulnerable to mutational
losses of its Cys residues.
The C3 mutations could be correlated with structure–function
relationships. The higher number of TED, MG2 and MG5 muta-
tions coincided with the location of the main CFH-binding site
between the TED–CUB domains and the MG1–MG2 domains
in the crystal structure of the C3b and CFH SCR-1/4 complex
[72]. The regulatory breakdown of C3b depended on the correct
relative positioning of these TED–CUB and MG1–MG2 domains
(Figure 5). In addition, the thioester bridge of the TED domain
binds to pathogenic targets, thus the TED missense mutations
may reflect its interactions with pathogens (Figure 5). The TED
domain also binds to complement receptors types 1 and 2 at
different contact sites, and these may be affected by missense
mutations in the TED domain [92].
The Arg102Gly missense mutation on the MG1 domain
defined a polymorphism that distinguished the major C3S and
C3F allotypes of C3. C3S was the most common of the two with
frequencies of 0.79 and 0.99 in Caucasian and Asian populations,
respectively. The functional polymorphism C3F was also iden-
tified as the rs2230199 SNP. C3S and C3F were distinguished
from their electrophoretic mobility on agarose gels, with C3S
moving slower and C3F faster [78]. Because the C3b crystal
structure showed that Arg102 on the MG1 domain was in prox-
imity to negatively charged TED residues, the Arg102Gly change
weakened the interaction of the TED–MG1 domain pair [54,90].
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
c© 2014 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/)
which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
643
E. Rodriguez and others
Figure 5 Distribution of the C3 missense mutations in the C3
crystal structure
The domains within the crystal structure of C3 are shown as a second-
ary structure ribbon. The functionally important TED domain is shown
in bright pink, and the adjacent CUB domain is shown in dark pink.
The location of the thioester residues in the TED domain are shown
as orange spheres. The MG1–MG8, C345C, LNK and ANA domains
are shown in light orange, except for the MG2 domain (yellow), MG5
domain (orange), MG-6 (blue) and MG8 domain (pale green) because
these four MG domains possess greater numbers of mutations. This
colour scheme mostly follows that for the sequence in Supplementary
Figure S4. The 45 residues associated with 47 missense mutations
are shown as dark blue spheres. The number of mutations within each
domain is written within brackets, and the mutations are identified in
Supplementary Figure S4.
DISCUSSION
In this study, the doubling of the available mutations in the FH–
HUS database, together with an almost complete set of crystal
structures for CFH, CFI, MCP and C3/C3b, provided novel in-
sight on the involvement of CFH, CFI, MCP and C3 with aHUS,
AMD and other inflammatory diseases. These four proteins are
crucial for the correct functioning of the AP, summarized in Fig-
ure 6(a). The combination of the mutations with structures per-
mits more accurate assessments of the consequence of a residue
change in an integrated view of complement activation and its
regulation. The complement system plays an important role in the
pathogenesis of aHUS and AMD, with C3/C3b being central to
this. Because all three complement activation pathways converge
at C3, the regulation of activated C3b is tightly controlled by CFH
or MCP as cofactor and CFI as protease. This would account for
the susceptibility of these four proteins to genetic alterations. If
complement is inefficiently regulated, host cells become subject
Figure 6 Schematic views of CFH and C3b binding to a host cell
surface
(a) CFH is represented by a green cartoon tube showing the 20 SCR do-
mains, with SCR-19/20 highlighted in blue. The SCR-1/4 domains are
shown bound to C3b in yellow. In C3b, unlike in C3, the TED domain is
extended to the base of the C3b structure. The CFI and MCP regulators
are drawn to the same scale using the same colouring of Figure 4. The
SP domain of CFI cleaves the CUB domain of C3b with CFH acting as
cofactor. (b) The CFH–C3b complex is shown as a cartoon in the same
orientation as in (a). CFH binds bivalently at its SCR-7 and SCR-20
domains to anionic charges on the heparan sulphate-coated host cell
surface (represented by heparin dp36). CFH also binds to covalently
linked C3d (TED) on host cell surfaces. This bivalent binding positions
the SCR-1/4 domains in a conformation that binds readily to C3b when
C3b is covalently bound to host cell surfaces through its thioester bond
in the TED domain. The C3b interaction with CFH results in the CFI-medi-
ated degradation of C3b to form C3d (the TED domain) and C3c, thereby
regulating complement activation at host cell surfaces. The TED, MG2
and MG5 domains showing the most C3b mutations are highlighted
in red. The SCR-19/20 domains that interact with C3d also possess
high levels of CFH mutations, also in red. The SCR-9 and SCR-15/17
domains that act as spacers of the SCR-6/8 and SCR-19/20 domains
also possess high levels of mutations, and are indicated in red.
to complement attack, resulting in tissue damage and a spectrum
of complement-related diseases. CFH was the first protein to be
associated with genetic disease, followed by CFI and MCP, and
then by C3/C3b. The number of mutations currently corresponds
to totals of 163 in CFH, 64 in CFI, 49 in MCP and 48 in C3. Of
these, 127 CFH mutations, 30 CFI mutations, 48 MCP mutations
and 36 C3 mutations were linked with aHUS patients. The non-
intronic mutational frequencies in these four proteins are 13 for
CFH, ten for CFI, nine for MCP and three for C3/C3b, each nor-
malized to 100 residues. Other complement proteins show much
reduced mutational frequencies [3,32].
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Although single mutations in CFH and C3 were enough to
predispose for aHUS, a low proportion of aHUS patients with
MCP or CFI mutations presented mutations in other comple-
ment proteins [32]. The CFH, CFI and MCP mutations have
been discussed previously [2]. Since that 2007 study, many new
C3 mutations have been identified. Patients with point mutations
at a 5′ donor splice site in the C3 gene produce dysfunctional
C3 protein, and show heightened susceptibility to bacterial in-
fections. The R1320Q mutation in the CUB domain occurs at
one of the two Arg–Ser sequences, which is cleaved by CFI,
leading to resistance to CFI-mediated cleavage [57]. Several C3
mutations have been implicated in AMD and aHUS, including
K65Q, K155Q, R161W, P314L and R102G. For example, the
K65Q variant in the MG1 domain causes decreased binding of
CFH to C3b [52], leading to inefficient complement inactivation
and endothelial damage to the glomeruli. The K155Q alteration
in the MG2 domain shows a ∼2.9-fold increased risk of AMD
[56]. The K155Q variant in C3 causes reduced CFH binding
to C3b, thus inhibiting the ability of CFH to regulate C3b. The
R161W variant in C3 causes hyperactive C3 convertase activity;
this change increased the binding of C3b to factor B and reduced
the binding of C3b to CFH and MCP, and resulted in a rapid
progression to end stage renal failure [57]. Interestingly, these
C3 variants involve replacements of positively charged residues.
Mutations in C3 often lead to the reduced binding of CFH and
MCP to the mutant C3b which is then less effectively regulated.
Other C3 mutants cause C3b to bind more strongly to factor B,
resulting in increased C3 convertase formation. Both scenarios
correspond to a ‘gain of function’ in C3 and C3b. In distinction to
these C3 mutations, mutations in CFH, CFI and MCP correspond
to a ‘loss of function’ in these three proteins, meaning also that
C3b is less regulated and exhibits an increase in activity, thus
leading to inflammation.
Mutations were generally explained in terms of their func-
tional consequences, although these explanations are not neces-
sarily definitive and some will require experimental validation.
For example, the R102G polymorphism is strongly associated
with aHUS and AMD [54], yet its function is unknown, and
the database will facilitate the design of experiments to probe
this. Comparison of the two binding sites for C3d on SCR-19/20
showed that three mutations in C3d and seven mutations in SCR-
19/20 are associated with the contact residues [84,85]. These can
likewise be tested through mutagenesis. Some anticipated muta-
tional hotspots were not observed in functional regions. However
this outcome has been seen with other proteins. For example,
14000 mutations were reported for the tumour suppression pro-
tein p53, but the effect of only about half of these could be ex-
plained [91]. The structural analysis of 1119 unique haemophilia
B mutations in the 415-residue coagulation protease factor IX
(including 604 missense mutations) revealed notably fewer muta-
tions in the Gla domain compared with the other three domains,
even though the membrane-binding Gla domain is essential for
function in factor IX [20].
Mutational hotspots were primarily identified in CFH and
C3/C3b (Figure 6b). For CFH, mutational hotspots were ob-
served for the SCR-19/20 and SCR-15/18 domains, but less so
for the SCR-1/4 and SCR-6/8 domains (Figure 6b). The SCR-
19/20 mutations may correlate with functional binding sites for
C3b/C3d and heparin. In the case of SCR-15/18, these domains
separate the two heparin-binding sites at SCR-6/8 and SCR-
19/20, thus mutations may affect the bivalent binding of CFH
to heparan sulphate-coated host cells [26]. Also C-reactive pro-
tein binds to SCR-16/20 and may be implicated with mutations
in this region [86]. Comparatively fewer CFH mutations were
observed for SCR-1/4 and SCR-6/8 even though these bind to
C3b and heparin, respectively. For MCP, the mutations in SCR-
1/4 may relate with MCP binding to C3b/C4b, similar to that of
CFH SCR-1/4. For CFI, which has a different domain structure
to those of CFH and MCP (Figure 4a), the broader occurrence of
mutations in its structure may be related to extensive interactions
of its SP domain with the CUB domain in C3b, and its SRCR
domain with the C345C domain in C3b (Figure 6a). C3/C3b dif-
fers in that many of its 13 domains are not disulphide-rich and
domain rearrangements occur when C3 is activated to C3b. A
given mutation may affect either C3 or C3b or both. The most
affected region in C3/C3b is the TED domain that contains the
reactive thioester group, followed by the nearby MG2 and MG5
domains (Figure 5). This mutational hotspot is explained by the
multiple roles of the TED domain. TED interacts covalently with
antigenic targets, as well as with the C-terminus of CFH and also
with complement receptors 1 and 2. These multiple interactions
may lead to the greater number of mutations observed in TED.
The updated database will assist immunologists to cross-
correlate mutations detected in these four different proteins for a
given patient. For example, for AMD patients, the database high-
lights the risk factors associated with associated polymorphisms,
and whether or not there are any links with aHUS. A clearer
definition of aHUS will assist the design of treatment strategies,
including decisions on transplants. The four proteins CFH, CFI,
MCP and C3/C3b show different patterns of mutational change.
The Type I phenotype corresponds to low protein levels caused
by misfolding or degradation events, whereas Type II phenotypes
correspond to the loss of functional activity in normal levels of
the protein. How individual CFH mutations may result in the
observed Type I and II phenotypes was previously discussed [2].
The larger number of CFH and MCP mutations compared with
CFI and C3 support the view that Type I phenotypes often result
from mutations in the four disulphide-linked Cys residues in the
consensus SCR domain, which tend to be at solvent-inaccessible
buried positions. Type II phenotypes may often result from
alterations in residues at surface-exposed positions. In this con-
text, the AMD-associated Tyr402His polymorphism and other
type II mutations associated with aHUS were located within the
hypervariable loop between β-strands β2 and β3, suggesting that
this exposed loop is often involved in function.
As well as suggesting future avenues of experiment, the com-
plement mutations will facilitate an evolutionary analysis of
the complement proteins. This was illustrated by an evolution
study of the coagulation proteins [94]. Complement is genet-
ically related to coagulation. Eleven human coagulation factors
were found in all vertebrates, suggesting that they emerged with
the first vertebrates around 500 Mya. Sequence analyses of 47
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genomes revealed that the coagulation system was under strong
selective pressures, perhaps to adapt against blood-invading
pathogens. Interestingly, the number of disease-causing muta-
tions was inversely related to the probability of positive selection.
When a site was under positive selection, it was less likely to ac-
quire disease-causing mutations. In contrast, sites under negative
selection were more likely to be associated with destabilizing
disease-causing mutations. A limited analysis of six genomes
suggested that positive selection occurred in nine complement
genes [82].
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